Otros idiomas CytoMed Therapeutics Limited

Acciones

GDTC

SGXZ17669631

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:00 21/05/2024			Varia. Cinco días.	Varia. 1 de enero.
2,04 ^USD	+0,49 %		-1,45 %	-58,37 %

22/04	CytoMed Therapeutics Limited informa de los resultados de ganancias para el año completo finalizado el 31 de diciembre de 2023	CI
18/03	CytoMed Therapeutics Limited lanzará un banco de células gratuito para accionistas cualificados para futuras terapias de precisión	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

CytoMed Therapeutics : PROXY STATEMENT AND NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K	24/04
CytoMed Therapeutics Limited Reports Earnings Results for the Full Year Ended December 31, 2023	22/04
Certain Ordinary Shares of CytoMed Therapeutics Limited are subject to a Lock-Up Agreement Ending on 14-APR-2024.	14/04
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies	18/03
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies	18/03
CytoMed Therapeutics Limited to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies	18/03
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair	04/03
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair	04/03
CytoMed Therapeutics Limited Announces Research Collaboration with Sengkang General Hospital Pte Ltd to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair	04/03
CytoMed Therapeutics Receives Patent in Malaysia for its Prospective Cancer Therapy	29/01
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology	29/01
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology	29/01
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology	05/12
CytoMed Therapeutics Limited Reports Earnings Results for the Half Year Ended June 30, 2023	17/11
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update	17/11
CytoMed Therapeutics to Present at the Benchmark Company s Upcoming Discovery One-on-One Investor Conference	15/11
CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference	14/11
Top Premarket Decliners	18/10/23
Chinese Patent Granted for CytoMed Therapeutics Licensed iPSC-Based Technology	26/09/23
CytoMed Therapeutics' iPSC-Based Technology Obtains Patent From Chinese Patent Office to Treat Cancer	25/09/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas CytoMed Therapeutics Limited

Acciones

GDTC

SGXZ17669631

Otros idiomas

Filtros